Melior Discovery Receives Patent Approval For Parkinson’s Disease Candidate

Melior Discovery, Inc. has recently announced that the United States Patent and Trademark Office (USTPO) granted the company a patent for MLR-1019, its Parkinson’s disease candidate. The patent includes the utilization of this therapeutic to address treatment for dyskinesia linked with L-DOPA therapy in Parkinson’s disease.

“This recent patent award will provide robust protection for MLR-1019 through 2034, and represents a significant milestone towards Melior’s second major development program,” noted Andrew Reaume who is the CEO and President of Melior Discovery.

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that causes motor symptoms such as rigidity, tremors, slowed movements and non-motor symptoms such as mood disorders, cognitive impairment and autonomic dysfunction. Parkinson’s disease levodopa-induced dyskinesia is an involuntary movement condition caused by levodopa-based therapy, the most commonly prescribed medicine for Parkinson’s disease.

MLR-1019 is an adjusted small molecule drug candidate that Melior is developing to treat Parkinson’s disease. Previous extensive animal model studies provided data showing MLR-1019 detains a unique property that attenuates patients’ dyskinesia while improving the therapeutic benefit of L-DOPA.

Melior Discovery is a sister company of Melior Pharmaceuticals, both leaders in pharmaceutical drug adjustment using the exquisite theraTRACE^® platform comprised of multiplexed in vivo disease models. Melior uses such capacities to construct an internal pipeline of advancement candidates, establishing partnerships with both biopharmaceutical and pharmaceutical firms to apply the theraTRACE^® platform and expertise.

Read More Recent News

Amarantus BioScience Holdings, Inc, recently announced the initiation of the first clinical site for its Phase 2b trial evaluating the efficacy of eltoprazine in the treatment of patients with Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Eltoprazine is a small 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). About 60-80% of patients with PD patients have PD-LID, a dyskinesia that can be severely disabling and impact quality of life as it disturbs patients’ ability to perform routine daily tasks.